Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

What predicts durable symptom relief of uterine fibroids treated with MRI-guided focused ultrasound? A multicenter trial in 8 academic centers.

What predicts durable symptom relief of uterine fibroids treated with MRI-guided focused ultrasound? A multicenter trial in 8 academic centers. European radiology Bitton, R. R., Fast, A., Vu, K. N., Lum, D. A., Chen, B., Hesley, G. K., Raman, S. S., Matsumoto, A. H., Price, T. M., Tempany, C., Dhawan, N., Dolen, E., Kohi, M., Fennessey, F. M., Ghanouni, P. 2023

Abstract

To identify variables predictive of durable clinical success after MRI-guided focused ultrasound (MRgFUS) treatment of uterine fibroids.In this prospective, multicenter trial, 99 women with symptomatic uterine fibroids were treated using MRgFUS. Pelvic MRI was obtained at baseline and treatment day. The Uterine Fibroid Symptom-Quality of Life questionnaire was used to calculate a symptom severity score (SSS) at baseline and 6, 12, 24, and 36 months following treatment. Clinical, imaging, and treatment variables were correlated with symptom reduction sustained through the 12- and 24-month time points using univariable and multivariable logistic regression analyses. A novel parameter, the ratio of non-perfused volume to total fibroid load (NPV/TFL), was developed to determine association with durable outcomes.Post-treatment, mean symptom severity decreased at the 6-, 12-, 24-, and 36-month follow-ups (p?

View details for DOI 10.1007/s00330-023-09984-4

View details for PubMedID 37553488

View details for PubMedCentralID 4561549